Screening for drugs of abuse: Which matrix, oral fluid or urine?

Annals of Clinical Biochemistry

Volumn 48, Issue 6, 2011, Pages 531-541

  Allen, Keith R ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE; BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE; MORPHINE 6 ACETATE; OPIATE;

ALCOHOL ABUSE; BODY FLUID; CANNABIS ADDICTION; CHEEK; CHROMATOGRAPHY; COCAINE DEPENDENCE; CONTAMINATION; DRUG ABUSE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LABORATORY DEVICE; METABOLITE; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; TANDEM MASS SPECTROMETRY; URINALYSIS; URINE;

ALCOHOLISM; ANIMALS; DRUG STABILITY; SALIVA; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 84856018095     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011116     Document Type: Review

References (96)

1. European roadside testing assessment. See http://www.rosita.org (last checked 22 March 2010)
2. Gerada C. Random drug testing in schools. Br J Gen Pract 2005;55:499-501
3. Office of Public Sector Information. See www.opsi.gov.uk (last checked 22 March 2010)
4. Home Office. See www.homeoffice.gov.uk/documents/cdlist.html (last checked 22 March 2010)
5. Allen KR, Azad R, Blake DK. Replacement of immunoassay by liquid chromatography tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid. Ann Clin Biochem 2005;42:277-84
6. Øiestad EL, Johansen U, Christophersen AS. Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. Clin Chem 2007;53:300-9
7. Cone EJ. Saliva testing for drugs of abuse. Ann NY Acad Sci 1993;694:91-127
8. Drummer OH. Drug testing in oral fluid. Clin Biochem 2006;27:147-59
9. Cone EJ, Huestis MA. Interpretation of oral fluid tests for drugs of abuse. Ann NY Acad Sci 2007;1098:51-103
10. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA. Metabolism of heroin and cocaine is catalysed by the same human carboxylesterases. J Pharmacol Exp Ther 1996;279:713-7
11. Rook EJ, Huitema DR, Van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharm 2006;1:109-18
12. Kupiec TC, Raj V, Vu N. Review: pharmacogenomics for the forensic toxicologist. J Anal Toxicol 2006;30:65-72
13. Kim I, Barnes AJ, Oyler JM, et al. Plasma and oral fluid codeine pharmacokinetics and pharmacodynamics after oral codeine administration. Clin Chem 2002;48:1486-96.
14. Schramm W, Craig PA, Smith RH, Berger GE. Cocaine and benzoylecgonine in saliva, serum and urine. Clin Chem 1993;39:481-7
15. Navarro M, Pichini S, Farré M, Ortuno J, Roset PN, Segura J. Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem 2001;47:1788-95
16. Proposed revisions to mandatory guidelines for federal workplace drug testing programs. Federal Register 2004;69:19698-700
17. SAMHSA. See http://www.workplace.samhsa.gov/DrugTesting/ (last checked 22 March 2010)
18. George S, Braithwaite RA. An investigation into the extent of possible dilution of specimens received for urinary drugs of abuse screening. Addiction 2006;90:967-70
19. Cone EJ, Lange R, Darwin WD. In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J Anal Toxicol 1998;22:460-73
20. Wu AHB, Bristol B, Sexton K, Cassalla-McLane G, Holtman V, Hill DW. Adulteration of urine by 'Urine Luck'. Clin Chem 1999;45:1051-7
21. Tsai JSC, ElSohly MA, Tsai S-F, Murphy TP, Twarowska B, Salamone SJ. Investigation of nitrite adulteration on the immunoassay and GC-MS analysis of cannabinoids in urine specimens. J Anal Toxicol 2000;24:708-14
22. Tsai S-CJ, ElSohly MA, Dubrovsky T, Twarowska B, Towt J, Salamone SJ. Determination of five abused drugs in nitrite-adulterated urine by immunoassay and gas chromatography-mass spectrometry. J Anal Toxicol 1998;22:474-80
23. Urry FM, Komaromy-Hiller G, Staley B, et al. Nitrite adulteration of workplace urine drug-testing specimens. Sources and associated concentrations of nitrite in urine and distinction between natural sources and adulteration. J Anal Toxicol 1998;22:89-95
24. George S, Braithwaite RA. The effect of glutaraldehyde adulteration of urine specimens on syva EMIT II drugs-of-abuse assays. J Anal Toxicol 1996;20:195-6
25. Cody JT, Valtier S, Kuhlman J. Analysis of morphine and codeine in samples adulterated with stealth. J Anal Toxicol 2001;25:572-5
26. Dasgupta A. The effects of adulterants and selected ingested compounds on drugs-of-abuse testing in urine. Am J Clin Pathol 2007;128:491-503
27. Wong RC, Tran M, Tung JK. Oral fluid drug tests: effects of adulterants and foodstuffs. Forensic Sci Int 2005;150:175-80
28. Dickson S, Park A, Nolan S, Kenworthy S, Nicholson C, Midgley J. The recovery of illicit drugs from oral fluid sampling devices. Forensic Sci Int 2007;165:78-84
29. Quintela O, Crouch DJ, Andrenyak DM. Recovery of drugs of abuse from the Immunalysis Quantisal oral fluid collection device. J Anal Toxicol 2006;30:614-6
30. Kauert GF, Iwersen-Bergmann S, Toennes SW. Assay of delta 9-tetrahydrocannabinol (THC) in oral fluid-evaluation of the OraSure oral specimen collection device. J Anal Toxicol 2006;30:274-7
31. Crouch D. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int 2005;150:165-73
32. O'Neil CL, Crouch DJ, Rollins DE, Fatah AA. The effects of collection methods on oral fluid codeine concentrations. J Anal Toxicol 2000;24:536-42
33. Kato K, Hillsgrove M, Weinhold L, Gorelick DA, Darwin WD, Cone EJ. Cocaine and metabolite excretion in saliva under stimulated and nonstimulated conditions. J Anal Toxicol 1993;17:338-41
34. Zaitsu K, Miki A, Katagi M, Tsuchihashi H. Long-term stability of various drugs in urine, and preventive measures against their decomposition with special attention to filtration sterilization. Forensic Sci Int 2008;174:189-96
35. Langel K, Engblom C, Pehrsson A, Gunnar T, Ariniemi K, Lillsunde P. Drug testing in oral fluid-evaluation of sample collection devices. J Anal Toxicol 2008;32:393-401
36. Ventura M, Pichini S, Ventura R, et al. Stability of drugs of abuse in oral fluid collection devices with purposes of external quality assessment schemes. Ther Drug Monit 2009;31:277-80
37. Samyn N, De Boeck G, Cirimele V, Verstraete A, Kintz P. Detection of flunitrazepam and 7-aminoflunitrazepam in oral fluid after controlled administration of rohypnol. J Anal Toxicol 2002;26:211-5
38. Moore C, Vincent M, Rana S, Coulter C, Agrawal A, Soares J. Stability of delta(9)-tetrahydrocannabinol (THC) in oral fluid using Quantisal collection device. Forensic Sci Int 2006;164:126-30
39. Fucci N, De Giovanni N. Stability of methadone and its main metabolite in oral fluid. Drug Metab Lett 2008;2:125-9
40. Jimenez C, de la Torre R, Ventura M, Segura J, Ventura R. Stability studies of amphetamine and ephidrine derivatives in urine. J Chromatogr B 2006;843:84-93
41. Moody DE, Monti KM, Spanbauer AC. Long-term stability of abused drugs and antiabuse chemotherapeutical agents stored at -20 degrees C. J Anal Toxicol 1999;23:535-40
42. Proposed revisions to mandatory guidelines for federal workplace drug testing programs. Federal Register 2004;69:19697-8
43. European Laboratory Guidelines for Legally Defensible Workplace Drug Testing. Version 1.0 2002. See http://www.aebm.org/documentos/drogas.pdf (last checked 22 March 2010)
44. United Kingdom Laboratory Guidelines for Legally Defensible Workplace Testing. Version 1.0. March 2001. See www.wdtforum.org.uk (last checked 22 March 2010)
45. Verstraete AG. Detection times of drugs of abuse in blood, urine and oral fluid. Ther Drug Monit 2004;26:200-5
46. Moffat AC, Osselton MD, Widdop B, eds. Clarke's Analysis of Drugs and Poisons. 3rd edn. Bath: Pharmaceutical Press, 2004:896
47. Musshoff F, Trafkowski J, Madea B. Validated assay for the determination of markers of illicit heroin in urine samples for the control of patients in a heroin prescription program. J Chromatogr B 2004;811:47-52
48. Cone EJ, Clarke J, Tsanaclis L. Prevalence and disposition of drugs of abuse and opiod treatment drugs in oral fluid. J Anal Toxicol 2007;31:424-33.
49. Krieger G, Krieger A, Stritt W, Vach W. Piotstudie zur Frage der Dosisabhangigkeit bei der Glucuronidierung von Morphin zu Morphin-3-bzw. Morphine-6-Glucuronid. Beitrage zur Gerichtlichen Medizin 1992;50:215-20
50. Staub C, Marset M, Mino A, Mangin P. Detection of acetylcodeine in urine as an indicator of illicit heroin use: method validation and results of a pilot study. Clin Chem 2001;47:301-7
51. Phillips SG, Allen KR. Acetylcodeine as a marker of illicit heroin abuse in oral fluid samples. J Anal Toxicol 2006;30:370-37
52. Dams R, Choo RE, Lambert WE, Jones H, Heustis MA. Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. Drug Alcohol Depend 2007;87:258-67
53. Pelders MG, Ros JJ. Poppy seeds: difference in morphine and codeine content and variation in inter- and intra-individual excretion. J Forensic Sci 1996;41:209-12
54. Rohrig TP, Moore C. The determination of morphine in urine and oral fluid following ingestion of poppy seeds. J Anal Toxicol 2003;27:449-52
55. Lafargue P, Benech H, Chaminade P, et al. Study of urinary excretion of codeine and morphine after oral ingestion of codeine. Ann Pharm Fr 1995;53:66-74
56. Mikus G, Weiss J. Influence of CYP2D6 genetics on opiod kinetics, metabolism and response. Curr Pharmacogenom 2005;3:43-52
57. Gossop M, Griffiths P, Strang J. Cocaine: patterns of use, route of administration and severity of dependence. Br J Psychol 1994;164:660-64
58. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine and codeine. Ther Drug Monit 2006;28:447-53.
59. Cone EJ, Tsadik J, Darwin WD. Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit 1998;20:556-60
60. Inchem. See http://www.inchem.org/documents/pims/pharm/pim139e.htm (last checked 22 March 2011)
61. Dams R, Choo RE, Lambert WE, Jones H, Huestis MA. Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. Drug Alcohol Depend 2007;87:258-67
62. Jufer R, Walsh SL, Cone EJ, Sampson-Cone A. Effect of repeated cocaine administration on detection times in oral fluid and urine. J Anal Toxicol 2006;30:458-62
63. Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev 2000;32:15-44
64. Oyler JM, Cone EJ, Joseph RE Jr, Moolchan ET, Huestis MA. Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin Chem 2002;48:1703-14
65. Schepers RJF, Oyler JM, Joseph RE, Cone EJ, Moolchan ET, Huestis MA. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 2003;49:121-32
66. Becket AH, Rowland M. Urinary kinetics of amphetamine in man. J Pharm Pharmacol 1965;17:628-38
67. Kintz P, Cirimele V, Ludes B. Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol 2000;24:557-61
68. Moore C, Ross W, Coulter C, et al. Detection of conjugated 11-nor-D9-tetrahydrocannabinol-9-carboxylic acid in oral fluid. J Anal Toxicol 2007;31:87-194
69. Goodwin RS, Darwin WD, Nora Chiang C, Shih M, Li Shou-Hua MA. Urinary elimination of 11-Nor-9-carboxy-9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008;32:562-69
70. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J AnalToxicol 2001;25:289-303
71. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of D9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 2007;31:288-93
72. Niedbala S, Kardos K, Salamore S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis smoke exposure and oral fluid testing. J Anal Toxicol 2004;28:546-52
73. Wurst FM, Skipper GE, Weinmann W. Ethyl glucuronide - the direct ethanol metabolite on the threshold from science to routine use. Addiction 2003;98:51-61
74. Hegstad S, Johnsen L, Mørland J, Christopherson AS. Determination of ethylglucuronide in oral fluid by ultra-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2009;33:204-7
75. Høiseth G, Bernard JP, Karinen R, et al. A pharmacokinetic study of ethyl glucuronide in blood and urine: application to forensic toxicology. Forensic Sci Int 2007;172:119-24
76. Shiran MR, Lennard MS, Iqbal MZ, et al. A. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharm 2008;67:29-37
77. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/pharmakodynmaic properties. J Pharmacol Toxicol Methods 1999;42: 61-6
78. Ferrari A, Coccia CPR, Bertolini A, Sternieri E. Methadone - metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-9
79. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44:989-1008
80. Ogu CC, maxa JL. Drug Interactions due to cytochrome P450. BUMC Proc 2000;13:421-3
81. Bernard J-P, Opdal MS, Karinen R, Mørland J, Khiabani HZ. Relationship between methadone and EDDP (2-ethylidene-1-,5-dimethyl-3,3-diphenylpyrrolidine) in urine samples from Norwegian prisons. Eur J Clin Pharm 2007;63:777-82
82. Kapur BM, Selby P, Latowsky M, Sing M, Koren G. CEDIA's EDDP immunoassay is a cost-effective compliance marker in an opiate dependency program. Clin Biochem 2000;33:230
83. Bennet GA, Davies E, Thomas P. Is oral fluid as accurate as urinalysis in detecting drug use in a treatment setting? Drug Alcohol Depend 2003;72:265-9
84. Cone EJ, Clarke J, Tsanaclis L. Prevalence and disposition of drugs of abuse and opiod treatment drugs in oral fluid. J Anal Toxicol 2007;31:424-33
85. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opiod dependence. Clin Pharmacokinet 2005;44:661-80
86. Kronstrand R, Seldén TG, Josefsson M. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J Anal Toxicol 2003;27:464-70
87. Fox EJ, Tetlow VA, Allen KR. Quantitative analysis of buprenorphine and norbuprenorphine in urine using liquid chromatography tandem mass spectrometry. J Anal Toxicol 2006;30:238-44
88. Benzodiazepine PK Pathway. See http://www.pharmgkb.org/do/serve?objId=PA165111375&objC1s=Pathway (last checked 22 March 2010)
89. Glover SJ, Allen KR. Measurement of benzodiazepines in urine; a comparison of liquid chromatography-tandem mass spectrometry against immunoassay. Ann Clin Biochem 2010;47:111-7
90. Moffat AC, Osselton MD, Widdop B, eds. Clarke's Analysis of Drugs and Poisons. 3rd edn. Bath: Pharmaceutical Press, 2004:775-6
91. DiGregorio GJ, Piraino AJ, Ruch E. Diazepam concentrations in patotid saliva, mixed saliva, and plasma. Clin Pharmacol Ther 1978;24:720-25
92. Smink BE, Hofman BJ, Dijkhuizen A, et al. The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. Br J Clin Pharmacol 2008;66:556-60
93. Smink BE, Mathijssen MPM, Lusthof KJ, de Gier JJ, Egberts ACG, Uges DRA. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines-like substances using immunoassay and LC-MS(-MS). J Anal Toxicol 2006;30:478-85
94. Moore C, Coulter C, Crompton K, Zumwalt M. Determination of benzodiazpines in oral fluid using LC-MS-MS. J Anal Toxicol 2007;31:596-600
95. Trathen B, Paterson S, Cordero R, Luty J. Validity of noscapine and papaverine metabolites as markers of heroin misuse in the context of diamorphine treatment. A survey of urine samples from non-substance misusing patients prescribed diamorphine. J Substance Use 2009;14:133-38
96. Brenneisen R, Hasler F, Würsch D. Acetylcodeine as a urinary marker to differentiate the use of street heroin and pharmaceutical heroin. J Anal Toxicol 2002;26:561-66